Adalimumab is a large molecule, protein-based drug commonly used in clinical practice to antagonize the effects of tumor necrosis factor. It is mainly used in diseases in which tumor necrosis factor is involved or its dominant action, such as rheumatoid arthritis and ankylosing spondylitis. The main effect is to relieve the damage to the joints, bones and peri-articular tissues associated with rheumatoid arthritis and ankylosing spondylitis, and also to improve the body’s function, thus providing relief from the symptoms of the disease. Adalimumab has a high safety profile with few side effects and can be an effective adjunct to the treatment of rheumatoid arthritis. For patients with ankylosing spondylitis, adalimumab can also significantly reduce inflammation in the spine and slow down the fibrosis and ossification of the intervertebral discs and surrounding tissues. In adult patients with severe ankylosing spondylitis, it can significantly improve the symptoms of spinal dysfunction with a rapid onset of action and significant efficacy.”